Paper Details

  1. Home
  2. Paper Details

Metabolism-based approaches for autosomal dominant polycystic kidney disease.

Author: BakajIvona, PocaiAlessandro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a condition that leads to end-stage kidney disease due to the development and expansion of multiple cysts in the kidneys. Tolvaptan, a vasopressin V2 receptor antagonist, has been approved for treating ADPKD patients at high risk of progression, but its use is limited due to poor tolerability, unfavorable safety profile, and high cost. This abstract explores new therapeutic opportunities targeting metabolic reprogramming in ADPKD to potentially minimize side effects and improve efficacy.
Paper Details　
Original Abstract of the Article :
Autosomal Dominant Polycystic Kidney Disease (ADPKD) leads to end stage kidney disease (ESKD) through the development and expansion of multiple cysts throughout the kidney parenchyma. An increase in cyclic adenosine monophosphate (cAMP) plays an important role in generating and maintaining fluid-fil...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980902/

データ提供：米国国立医学図書館（NLM）

Metabolic Approaches for Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) can feel like a desert slowly encroaching upon the kidneys, causing cysts to form and eventually leading to kidney failure. This study explores the metabolic changes occurring in ADPKD, suggesting that targeting these metabolic pathways could offer novel therapeutic opportunities.

Exploring New Avenues for Treatment

This study highlights the potential for metabolic reprogramming as a new target for ADPKD therapy, possibly leading to more effective and tolerable treatments than currently available options.

Personalized Approaches for ADPKD

The study's findings suggest that understanding the metabolic landscape of ADPKD could pave the way for personalized treatments tailored to each patient's individual needs, potentially improving treatment outcomes.

Dr. Camel's Conclusion

This research opens up new frontiers in the treatment of ADPKD, suggesting that targeting metabolic reprogramming could lead to more effective and personalized therapies for this challenging condition.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-07
Further Info :

Pubmed ID

36876046

DOI: Digital Object Identifier

PMC9980902

Related Literature

Article Analysis
・Side Effects of tolvaptan (kidney disease)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.